MapLight Therapeutics Q3 net loss widens 75% to $51.62 million
- MapLight Therapeutics’ third-quarter 2026 net loss widened 75% year over year to $51.62 million.
- R&D expenses rose 63% year over year to $44.21 million, while general and administrative expenses more than doubled to $11.14 million.
- Cash, cash equivalents and investments totaled $463.4 million at September 30, expected to fund operations through 2028.
- Start-up activities began for ZEPHYR-2, the planned Phase 3 schizophrenia trial of ML-007C-MA, with topline results expected in 2028.
- Enrollment continues in the Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160715PRIMZONEFULLFEED9878279) on November 16, 2026, and is solely responsible for the information contained therein.